

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A therapeutic agent for nerve damage comprising, as an active ingredient, a low-molecular-weight saccharide ~~composed of at least~~comprising glucuronic acid and/or N-acetylglucosamine or a pharmaceutically acceptable salt thereof.

2. (Currently Amended) The therapeutic agent according to claim 1, wherein the low-molecular-weight saccharide ~~composed at least glucuronic acid and/or N-acetylglucosamine~~ is a low-molecular-weight hyaluronic acid.

3. (Original) The therapeutic agent according to claim 2, wherein the low-molecular-weight hyaluronic acid is hyaluronic acid disaccharide to hyaluronic acid 2,500-saccharide.

4. (Original) The therapeutic agent according to claim 3, wherein the low-molecular-weight hyaluronic acid is hyaluronic acid disaccharide to hyaluronic acid 50-saccharide.

5. (Original) The therapeutic agent according to claim 4, wherein the low-molecular-weight hyaluronic acid is hyaluronic acid tetrasaccharide.

6. (Currently Amended) The therapeutic agent according to ~~any one of claims 1 to 5~~claim 1, wherein nerve damage is caused by spinal cord injury or nerve trauma.

7. (Currently Amended) A method of treating nerve damage, comprising administering an effective amount of a low-molecular-weight saccharide ~~composed of~~comprising at least glucuronic acid and/or N-acetylglucosamine or a pharmaceutically acceptable salt thereof to an animal suffering from nerve damage.

8. (Currently Amended) A method of manufacturing a therapeutic agent for nerve damage~~Use of which comprises dissolving~~ a low-molecular-weight saccharide ~~composed of at least~~comprising glucuronic acid and/or N-acetylglucosamine or a pharmaceutically acceptable salt thereof in a solvent commonly used for drugs~~manufacturing a therapeutic agent for nerve damage~~.